Laurus Labs rebound after poor Q3FY22 results as CDMO, API & Formulation segments witness growth but API segment continues to face headwinds | Q4FY22 Result Analysis
Laurus Labs rebound after poor Q3FY22 results as CDMO, API & Formulation segments witness growth but API segment continues to face headwinds | Q4FY22 Result Analysis
Laurus Labs rebound after poor Q3FY22 results as CDMO, API & Formulation segments witness growth but API segment continues to face headwinds | Q4FY22 Result Analysis